Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

Video

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Doxorubicin in combination with trabectedin has a high rate of hematologic toxicity, but this is manageable throughgranulocyte colony-stimulating factor, says Pautier. There was no toxic death observed in the study, according to Pautier. Patients were offered the possibility of surgery after 6 cycles of therapy.

One-quarter of patients in both groups can benefit from surgery with better results in terms of progression-free survival and overall survival, specifically those who undergo surgery after 6 cycles of therapy. The enhancement of response rates potentially permit more surgery in this particular patient population with locally advanced or metastatic disease, concludes Pautier.

Related Videos
John Shen, MD
Tatyana Feldman, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine